



897351
1-14



Ligand Component =
fCmGmGrArAtUfCmAmGfUmGmAmAtUmGfCfUfUmAtUmAtCmAtUfCfCmG-3'3'-dT
(VEGF ligand)

FIG. 1A




Ligand Component =
fCmGmGrArAtUfCmAmGfUmGmAmAtUmGfCfUfUmAtUmAtCmAtUfCfCmG-3'3'-dT
(VEGF ligand)

FIG. 1B


08897351.072197

897351
2-14



Ligand Component =
tCmGmGrArAtUfCmAmGfUmGmAmafUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT
(VEGF ligand)


FIG. 1C



Ligand Component =
tCmGmGrArAtUfCmAmGfUmGmAmafUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT
(VEGF ligand)

FIG. 1D

897351
3-14



NX31838 20Kb PEG


Ligand Component =

fCmGmGrArAtUfCmAmGfUmGmAmAtUmGfCfUfUmAtUmAtCmAtUfCfCmG-3'3'-dT

(VEGF ligand)


FIG. 1E

897351
4-14




C-5 Amino linker

FIG. 1F



Glycerol bisphosphate

FIG. 1G



18 atom spacer

FIG. 1H

06897351.072197
/512/015526890

897351
5-14




FIG. 11

897351-0219

897351
6-14

**VEGF Nucleic Acid Ligand
NX31838 Conjugated to
PEG20K and PEG40K:
Plasma Pharmacokinetics in
Sprague Dawley Rats
(dose 1 mg/kg)**




FIGURE 2

08097351.07497
26T229" T5E26880

897351
17-14

**VEGF Nucleic Acid Ligand
NX31838 Conjugated
to PL Lipid;
Plasma Pharmacokinetics
in Sprague Dawley Rats
(dose 1 mg/kg)**




FIGURE 3

891351
8-14




FIG. 4A

897351
9-14




FIG. 4B

897351
10-14




FIG. 4C

897351
11-14




FIG. 5A

451240 TEE 45830

897351
12-14






FIG. 5B

SECRET



897351
14-14

Figure 6: Pharmacokinetic Study of
Intravitreal Administration
of NX31838-40mPEG in Rabbits



08897351-07197
25 FEB 1990